DK2718326T3 - Antistoffer mod g-csfr og anvendelser deraf - Google Patents

Antistoffer mod g-csfr og anvendelser deraf Download PDF

Info

Publication number
DK2718326T3
DK2718326T3 DK12800867.9T DK12800867T DK2718326T3 DK 2718326 T3 DK2718326 T3 DK 2718326T3 DK 12800867 T DK12800867 T DK 12800867T DK 2718326 T3 DK2718326 T3 DK 2718326T3
Authority
DK
Denmark
Prior art keywords
csfr
antibodies
Prior art date
Application number
DK12800867.9T
Other languages
English (en)
Inventor
Andrew Donald Nash
Arna Elizabeth Andrews
Kirsten Mae Edwards
Matthew Philip Hardy
Con Panousis
Felicity Meredith Dunlop
Manuel Baca
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47353852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2718326(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of DK2718326T3 publication Critical patent/DK2718326T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK12800867.9T 2011-06-13 2012-06-13 Antistoffer mod g-csfr og anvendelser deraf DK2718326T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496351P 2011-06-13 2011-06-13
PCT/AU2012/000675 WO2012171057A1 (en) 2011-06-13 2012-06-13 Antibodies against g-csfr and uses thereof

Publications (1)

Publication Number Publication Date
DK2718326T3 true DK2718326T3 (da) 2020-10-26

Family

ID=47353852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12800867.9T DK2718326T3 (da) 2011-06-13 2012-06-13 Antistoffer mod g-csfr og anvendelser deraf

Country Status (15)

Country Link
US (5) US9193793B2 (da)
EP (1) EP2718326B1 (da)
JP (1) JP6187777B2 (da)
KR (1) KR101822702B1 (da)
CN (1) CN103649123B (da)
AU (1) AU2012269720B2 (da)
BR (1) BR112013031943B1 (da)
CA (1) CA2838246C (da)
DK (1) DK2718326T3 (da)
ES (1) ES2828482T3 (da)
IL (1) IL229468B (da)
MX (1) MX343580B (da)
RU (1) RU2605595C2 (da)
SG (1) SG195043A1 (da)
WO (1) WO2012171057A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
RU2020113060A (ru) * 2017-10-11 2021-11-12 Эланко Юс Инк. Варианты свиного g-csf и их применение
JP7465210B2 (ja) 2017-11-29 2024-04-10 シーエスエル リミティド 虚血-再灌流障害の治療又は予防方法
ES2940311T3 (es) 2018-07-13 2023-05-05 Alector Llc Anticuerpos anti-sortilina y métodos de uso de los mismos
CA3119192A1 (en) * 2018-12-04 2020-06-11 CSL Innovation Pty Ltd Method of treating neutrophilic conditions
US20220305133A1 (en) * 2019-06-12 2022-09-29 CSL Innovation Pty., Ltd. Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof
WO2021068074A1 (en) * 2019-10-08 2021-04-15 Zymeworks Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
EP4161576A1 (en) * 2020-06-04 2023-04-12 CSL Innovation Pty Ltd Method of treating or preventing acute respiratory distress syndrome

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
AUPM375194A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質/(ポリ)ペプチドライブラリー
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
CN103641885A (zh) 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1658095A4 (en) 2003-06-02 2006-06-14 Alexion Pharma Inc ANTI-CD3 ANTIBODY DESIMMUNISE
EP1751181B1 (en) 2004-06-02 2012-08-15 AdAlta Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
JP2009542197A (ja) * 2006-07-06 2009-12-03 メルク セローノ ソシエテ アノニム Csf3rポリペプチド及びそれらの使用
PL2056858T3 (pl) * 2006-08-11 2015-01-30 Csl Ltd Leczenie stanów chorobowych płuc
CN106220734A (zh) 2008-12-19 2016-12-14 宏观基因有限公司 共价双抗体及其用途
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
CN102630167B (zh) 2009-09-15 2015-06-10 Csl有限公司 神经病的治疗
US8968731B2 (en) 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis

Also Published As

Publication number Publication date
NZ617725A (en) 2015-02-27
EP2718326A4 (en) 2015-07-08
SG195043A1 (en) 2013-12-30
US20210009701A1 (en) 2021-01-14
AU2012269720B2 (en) 2015-01-22
CN103649123A (zh) 2014-03-19
MX343580B (es) 2016-11-10
WO2012171057A1 (en) 2012-12-20
KR101822702B1 (ko) 2018-01-26
CA2838246C (en) 2018-07-10
MX2013014711A (es) 2014-09-01
ES2828482T3 (es) 2021-05-26
CA2838246A1 (en) 2012-12-20
JP6187777B2 (ja) 2017-08-30
AU2012269720A1 (en) 2013-03-21
US20170226214A1 (en) 2017-08-10
EP2718326A1 (en) 2014-04-16
EP2718326B1 (en) 2020-08-19
CN103649123B (zh) 2017-05-24
US20120321630A1 (en) 2012-12-20
US20160031998A1 (en) 2016-02-04
US9193793B2 (en) 2015-11-24
IL229468B (en) 2021-05-31
JP2014519517A (ja) 2014-08-14
BR112013031943A2 (pt) 2016-11-22
RU2605595C2 (ru) 2016-12-20
US20190055313A1 (en) 2019-02-21
KR20140041717A (ko) 2014-04-04
RU2014100642A (ru) 2015-07-20
BR112013031943B1 (pt) 2021-10-13
IL229468A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CY2019040I2 (el) Aνti-il-23 αντισωματα
DK3556774T3 (da) Anti-CD40-antistoffer og anvendelser deraf
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
CO7020871A2 (es) Anticuerpos anti-il-36r
DK3495392T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112012030311A2 (pt) anticorpo
BR112012017441A2 (pt) compostos e métodos
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
CO6791565A2 (es) Anticuerpos anti-notch1
DK2718326T3 (da) Antistoffer mod g-csfr og anvendelser deraf
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2906597T3 (da) Antistoffer mod beta-amyloid
DK3202789T3 (da) Anti-vla-4-antistoffer
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
CO6841994A2 (es) Anticuerpos
DK2672837T4 (da) Ernæringssammensætning og anvendelser deraf
FR2977660B1 (fr) Regenerateur
FR2970154B1 (fr) Fermoir
ES1074298Y (es) Mondadientes
UA21869S (uk) Книжка записна
TH125972B (th) สมุด
ES1074688Y (es) Mochila
UA22106S (uk) Карбюратор